Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: ...

Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...

TARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...

TARRYTOWN, N.Y., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD ...

In 2022, Regeneron paid Sanofi $900 million to gain full rights to its partnered cancer drug Libtayo. Three years later, the pricey bet on the injected PD-1 inhibitor appears to be paying off.

Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space were PD-1 inhibitors such as cemiplimab (Libtayo; Regeneron) and ...

Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved label expansion of its PD-1 inhibitor Libtayo (cemiplimab). The EC approved Libtayo as an adjuvant ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...